

## **Senior Management**

### **Nancy Simonian, M.D., Chief Executive Officer**

Nancy has an established track record of value creation in biotechnology. Prior to Syros, she was Chief Medical Officer at Millennium Pharmaceuticals and, previously, Vice President of clinical development at Biogen. Nancy has overseen the development of the numerous medicines including AVONEX, TYSABRI, VELCADE, ENTYVIO as well as multiple drugs currently in development in oncology. Under Nancy's leadership at Millennium, Velcade became a mainstay of treatment for multiple myeloma, and a billion dollar commercial blockbuster. Nancy also built and advanced Millennium's promising pipeline of clinical stage drugs for cancer and inflammatory diseases. Nancy started her career as a member of the faculty at Harvard Medical School and neurology staff at Massachusetts General Hospital. She trained in neurology and internal medicine at the MGH and graduated with a degree in biology from Princeton. She is a member of the board of directors of Seattle Genetics, Inc., and formerly Arqule, Inc.

### **Eric R. Olson, Ph.D., Chief Scientific Officer**

Eric has over 25 years of experience in the life sciences industry. Prior to Syros, he was Research Vice President for respiratory diseases at Vertex Pharmaceuticals. During his 12 years at Vertex, he led research, development and commercial teams in bringing to patients the first cystic fibrosis (CF) treatment resulting from discovery of the CF gene. In addition to his work at Vertex Pharmaceuticals, Eric has also held positions as the Director of Antibacterials and Molecular Sciences departments at Warner-Lambert/Pfizer, as well as a research scientist focused on gene expression systems with The Upjohn Company. Eric earned his B.S. in microbiology from the University Minnesota and a Ph.D. in microbiology and immunology from the University of Michigan. He is published in more than 40 academic journals.

### **David A. Roth, M.D., Chief Medical Officer**

David brings more than 20 years of experience in industry and academic clinical research with a strong track record of successful oncology and hematology drug development. Prior to Syros, he was Executive Vice President and Chief Medical Officer of Infinity Pharmaceuticals and, previously, interim Co-head of Clinical Development and Vice President of Early Development in Pfizer's Oncology Business Unit. David joined Pfizer from Wyeth, where he held the roles of Assistant Vice President of Clinical Research & Development and Global Therapeutic Area Director of Hematology. While at Pfizer and Wyeth for over a decade, David contributed to the successful regulatory approval of several products, including Bosulif® (bosutinib), a dual Src/Abl tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia, Xyntha® and ReFacto AF® for the treatment of hemophilia A, and BeneFIX® for the treatment of hemophilia B. David also led the early development of Ibrance® (palbociclib), a CDK 4/6 inhibitor, which was awarded breakthrough status and subsequently received accelerated approval as a treatment for ER-positive, HER2-negative advanced breast cancer on a Phase 2 study. In addition to his extensive industry experience, David is an accomplished academic researcher and physician-scientist and was on the full-time faculty at Harvard Medical School and Beth

Israel Deaconess Medical Center in the Division of Hematology/Oncology. He completed his fellowship in hematology and oncology at Tufts-New England Medical Center and his Internal Medicine residency at the New England Deaconess Hospital in Boston. David received his B.S. from the Massachusetts Institute of Technology and his M.D. from Harvard Medical School in the Harvard-M.I.T. Division of Health Sciences and Technology.

**Gerald E. Quirk, Chief Legal Officer**

Gerald brings more than 20 years of senior leadership and legal experience in the biotechnology industry. Before joining Syros, he was Executive Vice President of Business Operations and General Counsel at Tokai Pharmaceuticals, where he was responsible for legal and business operations, including human resources, corporate communications and information technology. Prior to Tokai, Gerald was a partner and co-chair of the life sciences practice at Choate, Hall & Stewart LLP, a Boston law firm. In this role, he represented leading biopharmaceutical companies in corporate and securities law matters, financing and M&A transactions, and licensing and product development transactions. Before Choate, he was Vice President of Corporate Affairs and General Counsel at Infinity Pharmaceuticals with responsibility for the company's legal, intellectual property, finance and corporate communications activities, and prior to that, he held progressively responsible legal and business development positions at Genzyme Corporation. Gerald holds a B.A. in political science from Swarthmore College, an Ed.M. in educational administration from Harvard University and a J.D. from Northeastern University.

**Kyle Kusalanka, Chief Operating Officer**

Kyle brings more than 20 years of management, financial and strategy experience in the biopharmaceutical industry. Prior to Syros, he served as Chief Business Officer and Principal Financial and Accounting Officer of Blueprint Medicines, where he built the business organization, secured the company's first strategic collaboration and led the execution of the company's initial public offering. Before joining Blueprint Medicines, Kyle spent more than a decade at Millennium: The Takeda Oncology Company, where he served in a variety of business leadership roles, including as vice president of business development and corporate strategy. In this role, he was a member of the global oncology management team and portfolio review committee and led the overall strategic planning process for the therapeutic area with annual revenues in excess of \$2 billion and a broad pipeline of novel therapies. During his time at Millennium, Kyle also successfully identified and structured R&D and commercial-stage strategic business relationships and led the negotiations of multiple licensing and collaboration agreements. Earlier in his career at Millennium, he held leadership positions in finance and led the investor relations effort. Prior to Millennium, Kyle worked in strategy consulting for biopharmaceutical companies. He holds a B.A. from Wesleyan University and an MBA from the Wharton School of the University of Pennsylvania.